Does IDXX pay a dividend and is it safe?

IDEXX Laboratories Inc. (IDXX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / IDXX / dividends

LNTH (76) ORKA (53) NEOG (47) CLDX (29) ⌘ Pro Terminal →

IDEXX Laboratories Inc. (IDXX) Dividend Safety Gauge & 10-Year DRIP Compounder

$551.21 -4.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $548.27

IDEXX Laboratories Inc. (IDXX) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (61.8% gross margin, 30% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $43.42B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IDXX Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IDXX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, IDEXX Laboratories Inc. (NASDAQ: IDXX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $551.21 (-4.30% 1D, market cap $43.42B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IDXX ranks #72 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IDXX compare to LNTH and ORKA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), IDXX carries a Roarable B- (70/100 RQD), trailing P/E of 42.8x, gross margin of 61.8%, and ROIC of 29.6%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and ORKA (Oruka Therapeutics Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -18.8%, cap $6.41B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while IDXX leads on capital efficiency (29.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IDXX?

▼

Per IDXX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000874716), IDEXX Laboratories Inc. generated $4.30B in revenue (+10.4% YoY), $1.06B in net income, and $1.06B in free cash flow against $3.35B in total assets and $374.8M in total debt. Key quantitative strengths: Strong cash generator (61.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $548.29 (-0.53%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 24.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IDXX)Realized 20D OHLCV Swing Band: ±5.4%

Deterministic 5-Pillar Attribution (70/100 Composite)

🔍 WHY IDXX SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 24.6% FCF Margin ($1.06B FCF) & 61.8% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (26% of score)

Altman Z-Score 20.99 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (50.5) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$529.01+4.6% Next Q

Q2 (-2Q)

Grade C+$553.48+1.7% Next Q

Q3 (-1Q)

Grade B-$562.91-2.1% Next Q

Current

Grade B-$551.21+6.6% Hist 90D α

Trajectory: C+ (62) → B- (70)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IDXX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 70/100 (B-) score, IDXX faces multiple-compression risk if 42.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($535.00) or 200D SMA ($570.57) invalidates the momentum regime and cuts Target Base ($580.98) toward Bear Floor ($451.99).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IDXX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IDXX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 70%NO 30%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (7.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $20,610

Est. Year-10 Shareholder Yield: $371/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.8K

Yr 1

$11.6K

Yr 2

$12.4K

Yr 3

$13.4K

Yr 4

$14.4K

Yr 5

$15.4K

Yr 6

$16.6K

Yr 7

$17.8K

Yr 8

$19.2K

Yr 9

$20.6K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in IDXX & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on IDXX and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IDXX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.12%▼ DESCENDING CHANNEL

2026-11-03O $576.0H $576.0L $551.2C $551.2VOL 1.17M

RES: $584.2SUP: $490.2SMA50: $535.0SMA200: $570.6

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IDXX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IDXX Butterfly Map → + Track IDXX →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

32.2%/yr Implied 5Y Growth

vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IDXX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IDXX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IDXX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IDXX)

Health Care Rank #72 of 1015 ⚔️ LNTH vs IDXX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IDXX vs. LNTH, ORKA, NEOG, CLDX)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, IDEXX Laboratories Inc. (IDXX) ranks #72 by composite RQD confidence (70/100, grade B-) and #42 by equity capitalization ($43.42B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while IDXX leads on capital efficiency and profitability with 29.6% ROIC and 61.8% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with IDXX at 70/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IDXX ACTIVE IDEXX Laboratories Inc.	B-	70/100	42.8x	61.8%	29.6%	-4.30%	$43.42B	Benchmark Subject
LNTH Lantheus Holdings Inc.	B+	76/100	28.0x	61.1%	20.3%	+0.14%	$6.56B	/lnth-vs-idxx →
ORKA Oruka Therapeutics Inc.	D+	53/100	—	—	-18.8%	+0.23%	$6.41B	/orka-vs-idxx →
NEOG Neogen Corporation	D	47/100	—	46.9%	-0.6%	-3.59%	$2.58B	/neog-vs-idxx →
CLDX Celldex Therapeutics Inc.	E	29/100	—	87.1%	-35.0%	+0.70%	$2.36B	/cldx-vs-idxx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000874716 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IDEXX Laboratories Inc. (IDXX) reported GAAP revenue of $4.30B (+10.4% vs. FY2024 revenue of $3.90B , and +17.6% cumulative change since FY2023) , GAAP net income of $1.06B, operating cash flow of $1.18B, and free cash flow of $1.06B (+30.8% YoY). On the balance sheet, IDXX closed FY2025 with $3.35B in total assets against $374.8M in total debt (Altman Z-Score: 20.99, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.30B	$1.06B	$1.18B	$1.06B	$3.35B	$374.8M
FY2024 (FY)	2024-12-31	$3.90B	$887.9M	$929.0M	$808.1M	$3.29B	$449.8M
FY2023 (FY)	2023-12-31	$3.66B	$845.0M	$906.5M	$741.8M	$24.96B	$5.84B

3. IDXX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IDXX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IDXX compare to LNTH and ORKA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IDXX?

Where is IDXX trading relative to its 50-day, 200-day, and 52-week technical levels?

IDXX last traded at $551.21 (-4.30% on volume of 1,174,197 shares), positioning the stock +3.03% above its 50-day simple moving average ($535.00) and -3.39% below its 200-day simple moving average ($570.57). Across its 52-week range of $500.61 to $769.98, IDXX sits at the 18.8% percentile with a 14-day RSI of 50.5 (NEUTRAL RANGE) and an implied next-earnings move of ±5.4% ($521.44 to $580.98).

Direct Sub-Reports: IDXX RQD Cockpit IDXX 12M Forecast IDXX Earnings & Move IDXX Dividends & DRIP IDXX Insiders & 13F IDXX Whale Options IDXX Profit Sankey IDXX News & Why

ROARABLE RATING BRIEF • RQD 70/100 (B-) ✓ SEC XBRL & RQD VERIFIED

IDXX — IDEXX Laboratories Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

IDEXX Laboratories Inc. (IDXX) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $551.21 (-4.30% 1D, market capitalization $43.42B).

Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 29.6%, gross margin of 61.8%, operating margin of 31.6%, and free cash flow yield of 2.33%.
Whale 13F & Options Flow (10/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (18/20): Incorporates a 0.89x equity beta, Altman Z-Score of 20.99, Piotroski F-Score of 9/9, and Debt/Equity of 0.23x.

2. Business Model, Unit Margins & SEC Financial Trajectory

IDEXX Laboratories Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry (per the company profile). Specific product lines, customer segments, and revenue mix are — The profile does not describe how the company makes money beyond its sector classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), IDEXX Laboratories Inc. (IDXX) reported $4.30B in annual revenue (up from $3.90B in FY2024, +10.4% YoY) and $1.06B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.66B revenue, $845.0M net income) through FY2025, IDXX scaled operating cash flow to $1.18B and free cash flow to $1.06B, backed by $3.35B in total assets against $374.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B- • RQD 70/100): Strong cash generator (61.8% gross margin)—profits are backed by real money, not accounting tricks. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $500.61 – $769.98 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 42.8x trailing P/E and 31.1x EV/EBITDA against 31.6% operating margins and a 0.89x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), IDXX carries a macro regime beta of 0.89 and gross margin of 61.8%.

Key Question #1: Can IDXX sustain or expand its 31.6% operating margin and 29.6% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $4.30B and free cash flow of $1.06B, how will capital allocation balance growth reinvestment against $374.8M in total debt?
Key Question #3: How sensitive is IDXX's 39.8x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.89x)?

IDXX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IDEXX Laboratories Inc. (IDXX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IDXX Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

IDEXX Laboratories (IDXX) Rebounds On Jefferies Support, Is It Still 20% Undervalued?

Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Idexx Laboratories Stock Price Forecast. Should You Buy IDXX?

StockInvest.us report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

IDEXX Laboratories (IDXX) Stock Looks Fairly Valued Despite Its 28% Run

Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

KeyBanc initiates Idexx Laboratories stock rating at Sector Weight

Investing.com report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

IDEXX Laboratories (IDXX) Reports Q3 Revenue Beat, Shares Trade Below GF Value™

GuruFocus report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

IDEXX Laboratories (IDXX) vs. ZTS and NEOG: Can Raised Guidance and Product Expansion Drive Further Earnings Growth?

Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

IDEXX Laboratories Inc (IDXX) Shares Surge 3.4% -- What GF Score of 96 Tells Investors

GuruFocus report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

IDEXX Laboratories Reports Soon: How Has The Stock Reacted To Past Earnings?

Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IDXX Bull vs. Bear Conversation Board — What's Your Call at $551.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IDXX 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $650.43 (+18.0%)

📌 Pinned Debate

The stock carries a 29.6% ROIC, an Altman Z of 20.99, and a Piotroski F of 9/9, supported by revenue growth from $3.66B to $4.30B a

Here is why I am bullish on IDXX here at $551.21: The stock carries a 29.6% ROIC, an Altman Z of 20.99, and a Piotroski F of 9/9, supported by revenue growth from $3.66B to $4.30B across three fiscal years.. Compare IDXX's 31.6% operating margin and 29.6% ROIC against the rest of Biotechnology: In Vitro & In Vivo Diagnostic Substances. As long as cash conversion holds up, dips toward $523.65 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — IDXX's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $468.53 (-15.0%)

Spot @ $551.21

At a P/E (TTM) of 42.8 and EV/EBITDA of 31.1, with a 2.33% FCF yield, the valuation leaves little room for growth to disappoint.

At a P/E (TTM) of 42.8 and EV/EBITDA of 31.1, with a 2.33% FCF yield, the valuation leaves little room for growth to disappoint.. Look at the math on IDXX: paying 42.8x trailing P/E for 29.6% ROIC and 31.6% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $485.06 before getting long.